Comparative Effectiveness of Valoctocogene Roxaparvovec and Efanesoctocog Alfa in the Treatment of Severe Hemophilia A: A Matching-Adjusted Indirect Comparison of Bleeding Frequency
This MAIC suggests that valoctocogene roxaparvovec provides a greater likelihood of patients experiencing zero treated bleeds compared with efanesoctocog alfa during the first year following treatment initiation.
Authors
- Kurt Taylor (ORCID: https://orcid.org/0000-0003-4690-063X)
- Anthony J. Hatswell (ORCID: https://orcid.org/0000-0003-1129-326X)
- Sandra Santos‐Martínez (ORCID: https://orcid.org/0000-0003-4244-6919)
- David Hinds (ORCID: https://orcid.org/0000-0003-0219-9941)
- T. Douglas
Institutions
- University of Nottingham (GB)
- BioMarin (United Kingdom) (GB)
- University College London (GB)
- BioMarin (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1007/s12325-025-03339-9
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00